Clock

Clock

Nothing in this setup resets on a calendar. The re-rating path runs through printed quarters: Q2 2026 on August 6, the first Publicis-clean quarter in early November, and the quarter where consensus itself has growth reaccelerating — Q4 2026, printed late February 2027. This name's own history holds no drawdown of comparable depth; the deepest prior, 64% in 2021–22, took 2.9 years round trip. Listed options run to January 2028; 30-day implied volatility was 84.6% on July 24, 2026.

The Re-Rating Mechanism

The framework's strongest clock is an industry that reprices on a schedule — premiums reset, contracts renew, and mean reversion happens whether or not the company executes. Programmatic advertising has no such schedule. There is no regulated rate filing, no annual premium round, no cost-trend true-up. What TTD has instead is a set of mechanisms with different degrees of "already in motion," and none of them is mechanical.

Growth stabilizing against an easier base. Reported revenue growth has decelerated in four consecutive quarters, from 25.4% in Q1 2025 to 11.8% in Q1 2026. Management guided Q2 2026 to "at least $750 million" [1], which computes to 8.1% growth against the $694.0M Q2 2025 base. Consensus places the trough there and has growth back to 11.0% by Q4 2026. Evidence it is in motion: TTD signed 45 joint business plans in March 2026 alone, with total JBP count up 55% year over year and new-deal spend up 40% [2]. Window: visible in the Q3 2026 print (early November 2026) and confirmable in Q4 2026 (late February 2027).

A named counterparty dispute rolling off. Publicis paused client spend on the platform in March 2026 following an agency-commissioned audit of TTD fee practices; the two settled privately and the agency resumed in June 2026 [3]. On the Q1 call the CEO said only that "our negotiations are ongoing" about the next chapter of the partnership [4]. The arithmetic consequence is a calendar one: the pause sits inside the April–June quarter that reports on August 6, and Q3 2026 is the first quarter carrying restored spend for its full length.

The denominator. $327 million remained authorized for repurchase at March 31, 2026 [5]. At the $17.29 close of July 24, 2026 that retires 18.9 million shares, or 4.0% of the 471.0 million Class A and Class B shares outstanding at quarter-end (427.890M plus 43.109M) [6]. The counter-fact sits in the same filing: the program is "designed to help offset the impact of future share dilution from employee stock issuances" [7], and Q1 2026 stock-based compensation ran $109 million (total operating expense of $622 million against $513 million excluding SBC) [8] — roughly $436 million annualized, more than the remaining authorization. Net of issuance, the outstanding count fell 1.03% in the quarter, from 475.923M to 470.999M [9]. Successive top-ups have been shrinking even as the price fell: $647 million in February 2024, $564 million at end-January 2025, $500 million in October 2025, $350 million in February 2026 [10]. The share-count mechanics are worked in full in Self-Help.

A feared event failing to happen. The fear is displacement of the CTV franchise by a demand-side platform owned by an inventory owner; the FY2025 10-K names the shape of it, describing competitors that "are divisions of large, well-established companies such as Google and Amazon" [11]. This one has no date attached to it at all. TTD does not disclose CTV revenue, so the only quarterly read is channel mix — video including CTV was a low-50s percentage of the business in Q1 2026 and still rising as a share of mix [12]. Absence of displacement is provable only by accumulation, which is the slowest form of proof.

Cost normalization is not available here. Management guided the full-year 2026 adjusted EBITDA margin to "at least 40%, approximately in line with 2025" [13], and Q1 operating expense excluding SBC grew 18% against 12% revenue growth [14]. There is no depressed margin waiting to recover, so no margin-recovery catalyst exists to be dated.

Dated Catalysts

Sources: Q2 2026 reporting date, Publicis resolution and CFO appointment from the news record [15]; guidance from the Q1 FY2026 call [16]; repurchase authorization from the Q1 FY2026 Form 10-Q [17] and the February authorization pattern from its Item 2 repurchase disclosure [18]; litigation status from the same filing [19]; consensus quarterly revenue from CapIQ estimates.

Two of these deserve their timing stated rather than assumed. The securities class action — brought over alleged Kokai misstatements [20], on behalf of purchasers between November 15, 2023 and August 8, 2025 — survived dismissal in full on March 17, 2026, with the company filing its answer on April 30, 2026 and describing the case as "still in its early stages" [21]; the consolidated derivative actions are stayed "until the close of fact discovery in the securities class action" [22]. A securities case entering discovery in mid-2026 does not resolve inside the 18-month window; it is an overhang that persists through it, not a catalyst within it.

The second is insider conviction, which arrived on a date and at a price. Form 4s filed March 4, 2026 record CEO Jeff Green buying 6,000,000 Class A shares on March 2–4 for $148.1 million, at an average of about $24.68 [23]. The stock rose 18.4% on March 5, 2026, the session after the filing. The counter-facts are in the same register and the same filing: director Kathryn Falberg sold 152,828 shares on March 5 at $30.45–30.48 [24], and the company's own March repurchases of 7.1 million shares were executed at an average of $24.31 [25]. At $17.29 both the CEO and the company are roughly 29–30% underwater on those purchases, and the March re-rating they produced has fully unwound.

Drawdown Base Rates

Since the September 2016 listing, TTD has had eight drawdowns of 30% or more measured on closing prices. Seven completed and recovered to the prior peak; the eighth is the current one.

Source: derived from the run's daily closing-price series, 21-Sep-2016 to 24-Jul-2026; episodes defined as a fall of 30% or more from a running peak close, with the trough taken as the lowest close before the prior peak is regained. Company filings, as reported.

Source: derived from the run's daily closing-price series; months computed as calendar days divided by 30.44. The Dec 2024 episode has no round-trip figure because the prior peak has not been regained. Company filings, as reported.

The arithmetic a skeptic should recompute: the current depth is 16.79 divided by 139.51 minus one, or −87.97%, over 596 calendar days from the December 4, 2024 peak to the July 23, 2026 low — which was set one session before the July 24 close of $17.29. The deepest prior episode is 39.89 divided by 111.64 minus one, or −64.27%, over 358 days to trough and 1,053 days (2.88 years) from peak back to peak.

Across the seven completed episodes the median depth was 35.6%, the median time to trough 89 days, and the median round trip 165 days — a little under six months. The current episode is 24 percentage points deeper than anything in the record and has already run 6.7 times the median length to a trough that is only provisional. This name's history contains no precedent for the present episode, and the base rate therefore cannot be read as a timing estimate.

The 2021–22 episode is the closest analogue in kind, and it is instructive precisely because it was not an earnings event: revenue grew 31.9% that year, from $1,196M in FY2021 to $1,578M in FY2022, while the stock fell 64.3%. That is the quality-franchise pattern — price swinging far more than value — and it took 2.88 years to unwind. The present episode does not have the same anatomy. Revenue has kept growing (FY2024 $2,445M, FY2025 $2,896M, FY2026 consensus $3,177M), but the growth rate has gone from 25.6% to a consensus 9.7%, so this is a de-rating with a deceleration inside it rather than pure multiple compression. On sales multiples: about 28.6 times FY2024 revenue at the December 2024 peak (139.51 times 501.9M shares), against 2.7 times FY2026 consensus revenue at the current $8.53 billion market cap. That range is also the framework's first hard exclusion — a high-growth name on an extreme multiple to sales — and it applied to this name at the peak; the universe test on the current $8.53 billion capitalization against the framework's $10 billion floor is worked in Fit and Business.

One base rate does exist and is worth stating with its caveat. Measuring forward from each of the seven prior troughs, the median 12-month gain was +171% and the median 24-month gain +377%. Every one of those troughs occurred while revenue was compounding between 23% and 55% a year. Consensus for FY2026 is 9.7% and for FY2027 9.6%. The recovery base rate is drawn from a materially different business, and applying it to the current one would be a category error.

Street Positioning

Source: CapIQ street consensus as captured in this run (30 target-price contributors, 36 rating contributors); price from the run's daily closing-price series, 24-Jul-2026.

Source: CapIQ consensus recommendation detail as captured in this run; consensus recommendation score 2.53 on a 1-to-5 scale.

The sell side has moved its ratings but not its numbers. Nineteen of thirty-six analysts sit at hold and four more at underperform or sell, producing a consensus score of 2.53 — the distribution of a group that has stopped defending the story. Yet the mean target of $24.32 is 40.7% above the last close, the median $24.50, and the range runs from $11 to $38 — a 3.5-times spread between the low and high marks. That dispersion is the signature of an unresolved binary rather than a capitulated tape: the low mark implies 36.4% further downside from here, the high mark implies the stock roughly doubling, and the same set of forecasters holds both.

The forward numbers have not capitulated either. Consensus free cash flow computes to a 9.1% yield on the $8.53 billion market cap for FY2026, 10.4% for FY2027 and 11.3% for FY2028 (fit_features.consensus_forward_yield). Under the framework's consensus check, that is the configuration where the sell side's own estimates clear the moderate bar while the tape prices something considerably worse. One qualification belongs with it: consensus free cash flow is struck before stock-based compensation, and the framework's adjusted basis subtracts SBC — which ran $109 million against $276 million of Q1 2026 free cash flow [26]. The deterministic feature file could not compute adjusted FCF for any year (SBC is absent from the structured cash-flow record), so the adjusted yield and its position against the 10% bar are established in Yield, not here.

The Candidate Quarter

Source: reported revenue from the run's quarterly income statements (Q1 2025 $616.0M through Q1 2026 $688.9M); forward quarters from CapIQ consensus means ($751.6M, $804.7M, $940.1M). Company filings, as reported.

Consensus itself answers the question of when recovery shows up in printed numbers: it does not expect one. It expects a trough and a partial recovery. The 8.3% consensus for Q2 2026 is the low point of the series, Q3 recovers 0.5 of a percentage point to 8.8%, and Q4 2026 reaches 11.0% — still below the 11.8% just reported. Full-year 2026 computes to 9.7% and 2027 to 9.6%, so consensus has growth settling in the high single digits to low double digits rather than returning to the twenties.

That makes Q4 2026, printed in late February 2027, the candidate quarter — the first period where consensus has growth accelerating rather than decelerating, on a base ($846.8M in Q4 2025) that already reflected the deceleration. It sits about nineteen months from today. The quarter before it, Q3 2026 in early November, is the more informative one for the mechanism rather than the re-rating: it is the first quarter carrying restored Publicis spend for its full length, and the first full quarter under the new CFO, so a Q3 print at or below the Q2 growth rate would say the deceleration is not a counterparty effect.

The 18-Month Read

Re-recognition toward the street's own mean target inside 18 to 24 months is a reasonable expectation on the evidence assembled here, and recovery of the drawdown itself is not. The distinction matters because the two carry different arithmetic: the mean target of $24.32 asks for 40.7% and requires only that the consensus trough hold and print; the December 2024 peak asks for 707% and has no support in the mechanism list at all.

The evidence for the first half of that read: the price at $17.29 is discounting materially worse than consensus, which still carries FY2027 revenue growth of 9.6% and free cash flow of $883 million; the two dated mechanisms with the shortest fuses (Publicis spend restored June 2026; $327 million of authorization at a price that retires 4.0% of the shares) are both in motion now; and consensus itself puts the growth trough in the quarter reporting August 6, 2026.

The evidence against the second half, and the harder constraint: nothing here resets mechanically. Every mechanism above requires the business to print, which makes this an execution clock — the slowest kind. The one comparable-depth episode in this name's own record took 2.88 years peak to peak from 24 points less depth, and it recovered on 32% revenue growth that no longer exists. The securities litigation entered discovery in 2026 and runs through the whole window. Three CFOs in twelve months means the executive who will own the guidance has been in the seat since July 9, 2026 [27], and the current low was set on July 23, 2026 — one session before the last close — so there is not yet a trough to date the clock from.

What would falsify the read: a Q3 2026 print (early November 2026) with revenue growth at or below the Q2 trough rate of roughly 8% with Publicis spend restored for the full quarter, or a cut to the "at least 40%" full-year 2026 adjusted EBITDA margin guide [28]. Either would move the diagnosis from a cyclical and counterparty trough to structural share loss, at which point the mechanism list above has nothing left in it. This is the name-specific version of the framework's "repricing cycle fails to materialize" falsifier, and it is carried into the ledger in Fit.

Instrument Facts

Stated as facts, with their dates.

Long-dated listed options exist. The TTD option chain quoted on July 24, 2026 (last price $17.29, matching that session's close) carries expirations through January 21, 2028 — approximately 18 months forward — alongside January 15, 2027, March 19, 2027 and June 17, 2027 (source: Stock Options Channel TTD option chain, as of the July 24, 2026 close). Because qualifying long-dated contracts exist, the framework's watchlist-only routing for names without them does not apply to TTD.

Liquidity, at a high level. That same July 24, 2026 session showed 24,599 call contracts and 10,162 put contracts traded, a put-to-call volume ratio of 0.41 (source: Stock Options Channel, July 24, 2026). The underlying is an S&P 500 constituent, added July 18, 2025 [29], and traded a 20-day average of 12.7 million shares, or $236 million a day, through July 24, 2026 (run technical data). Aggregate open interest could not be obtained from a citable source; the volume figures above are the liquidity evidence this tab can stand behind.

Implied volatility, dated. TTD's 30-day mean implied volatility was 84.63% and its 180-day mean implied volatility 72.54%, both for the session dated 2026-07-24 (source: AlphaQuery TTD option volatility statistics, figures for 2026-07-24). The framework's reference lines are up to roughly 50–55 as acceptable and 60–70 as elevated; both figures sit above that elevated band — the 180-day measure by 2.5 points and the 30-day measure by 14.6 points, taking 70 as the upper edge. The 30-day figure spans the August 6, 2026 earnings date, which mechanically lifts it; the 180-day figure is the closer read on the long-dated part of the curve, and it is still above the band.

No strike, expiry, structure, or sizing is suggested anywhere in this tab. These are the instrument facts as of July 24, 2026; the framework's use of them belongs to the reader.